Universal Beteiligungs und Servicegesellschaft mbH Buys 39,838 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 77.0% during the third quarter, Holdings Channel.com reports. The fund owned 91,590 shares of the company’s stock after buying an additional 39,838 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Tarsus Pharmaceuticals were worth $5,443,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 26.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after purchasing an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Tarsus Pharmaceuticals by 220.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares during the last quarter. West Wealth Group LLC bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at $202,000. Finally, Allianz Asset Management GmbH bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $227,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on TARS shares. Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $51.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday. Barclays began coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Finally, HC Wainwright raised their price objective on Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $79.86.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at $3,120,535.80. The trade was a 15.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $67.94 on Tuesday. The firm has a market cap of $2.88 billion, a P/E ratio of -33.63, a price-to-earnings-growth ratio of 0.99 and a beta of 0.59. The business’s 50 day moving average is $78.50 and its 200-day moving average is $64.90. The company has a current ratio of 4.29, a quick ratio of 4.25 and a debt-to-equity ratio of 0.22. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.The firm had revenue of $118.70 million for the quarter, compared to analyst estimates of $114.22 million. Equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.